• Restores endogenous insulin production via pancreatic β-cell regeneration/protection

• Reduces adiposity through metabolic reprogramming—not appetite suppression

• Demonstrates efficacy in both lean and obese preclinical models

• Is backed by peer-reviewed publications and a granted U.S. patent

​

“Analysts project the global GLP‑1 receptor agonist market to reach more that $150 billion by 2030, driven by its expanding applications across type 2 diabetes, obesity, and metabolic disease Metabolica is going a step further — targeting the root cause with a regenerative, oral approach that aims to restore metabolic function that promises to fix the system.”

— Dr. Daniel Auld, CEO, Metabolica Health

​

Market Opportunity: Diabetes, Obesity & NAFLD

Metabolica Health is developing a single, oral, patent-protected molecule that targets the biological root of metabolic dysfunction — with clinical potential in type 2 diabetes, obesity, and NAFLD/NASH.

​

By 2030:

• Type 2 Diabetes: The global type 2 diabetes treatment market is expected to reach $91.97 billion by 2030, driven by demand for safer, more effective therapies that go beyond symptom control.[1]

• Obesity: The anti-obesity drug market is projected to grow from $6.62 billion in 2023 to $77.24 billion by 2030, with a CAGR of 31.66%, reflecting rising adoption of new therapies and unmet needs for durable, non-injectable options.[2] Analysts at Morgan Stanley project larger global obesity drug market potential at $105 billion by 2030, driven by high demand for GLP-1 therapies.[3] This is despite their injectable delivery, high cost, and significant side effects.

• NAFLD/NASH: The non-alcoholic fatty liver disease (NAFLD)/NASH therapeutics market is projected to reach $33.80 billion by 2030, with growing interest in metabolic and microbiome-based therapies.[4]

 

 

Metabolica Health’s lead compound, 4-cresol, is a regenerative small molecule that:

✅ Stimulates β-cell regeneration and insulin secretion in diabetes

✅ Reduces adiposity through systemic metabolic reprogramming

✅ Improves liver fat metabolism, supporting therapeutic potential in NAFLD/NASH

​

Metabolica isn’t just pursuing a treatment—it’s a new class of therapy addressing the biological root of metabolic disease. For patients, it offers the potential for durable, side-effect-sparing outcomes.

​

For investors, it presents a platform opportunity across ~$200B in combined market value by 2030, backed by clear IP, clinical momentum, and scalable impact.

​

“A paradigm-shifting therapy targeting the root of metabolic disease including diabetes, obesity and liver disease—with potential for combination, prevention, and long-term use—in market that could exceed $200B with expanded indications. And we own the IP.”

​

Why Metabolica Health? A Clear Competitive Advantage

​

Metformin has been the first-line treatment for type 2 diabetes for decades. GLP-1 agonists have since expanded the treatment landscape, especially for patients with obesity.

Yet neither addresses the root biological dysfunction—and neither restores, protects, or rebuilds the body’s insulin-producing β-cells. 4-cresol offers the potential to change that.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

 

 

Highlights of Metabolica’s Multi-Indication Platform

1. Type 2 Diabetes — Regenerates β-cells and restores glycemic regulation

2. Obesity — Reprograms systemic metabolism; reduces fat mass in lean and obese models

3. NAFLD/NASH — Improves insulin sensitivity and adiposity; potential impact on liver fat and inflammation

 

Contact

Metabolica Health Inc.
📧 Email: dan@metabolicahealth.com
Request the full investor presentation or schedule a call

​

[1] https://www.grandviewresearch.com/industry-analysis/type-2-diabetes-treatment-market-report | Report ID: GVR-4-68040-430-4

[2] https://www.grandviewresearch.com/industry-analysis/anti-obesity-therapeutics-market |

Report ID: GVR-4-68040-235-6

[3] Morgan Stanley Research (May 2024) Forecasts obesity drug market will reach $105 billion by 2030, driven by GLP-1 expansion.
https://www.morganstanley.com/ideas/obesity-drugs-market-expanded-opportunit

[4] https://www.grandviewresearch.com/industry-analysis/non-alcoholic-steatohepatitis-nash-treatment-market-report   | Report ID: GVR-4-68039